Dacomitinib
id:
dacomitinib-227-4066196
title:
Dacomitinib
text:
Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR. Dacomitinib has advanced to several Phase III clinical trials. In January 2014 results of the first trials were disappointing, with a failure to meet the study goals, but additional Phase III trials continued. In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC were announced. Dacomitinib was approv
brand slug:
wiki
category slug:
encyclopedia
description:
Drug for the treatment of lung carninoma
original url:
https://en.wikipedia.org/wiki/Dacomitinib
date created:
2014-02-25T18:33:17Z
date modified:
2024-09-15T02:00:02Z
main entity:
{"identifier":"Q17130597","url":"https://www.wikidata.org/entity/Q17130597"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/1/1e/Dacomitinib.svg","width":512,"height":252}
fields total:
13
integrity:
16